Spirochetes, Cell-Wall-Deficient, and Intracellular Agents
A page for organisms that do not fit routine Gram stain and plate logic, including Treponema, Borrelia, Leptospira, Mycoplasma, Chlamydia, Rickettsia, and Coxiella.
Core idea
Spirochetes, Cell-Wall-Deficient, and Intracellular Agents gives students a place to organize the topic before memorizing organism lists, test names, or isolated exam facts.
Principle
Learn this topic by asking what the specimen, method, organism group, and clinical setting are trying to prove. Build the topic around practical study anchors and bench reasoning.
Visual reactions
Study Organizer
| Anchor | What to learn first | Why it matters |
|---|---|---|
| Treponemes | venereal and nonvenereal disease patterns, serology algorithms, and titer follow-up | Use this as a branch point for review, tables, and practice questions. |
| Borrelia and Leptospira | exposure history, staged illness, and specimen timing organize testing | Use this as a branch point for review, tables, and practice questions. |
| Chlamydia/Rickettsial agents | intracellular biology changes culture and testing expectations | Use this as a branch point for review, tables, and practice questions. |
| Mycoplasma/Ureaplasma | no cell wall, special collection, and NAAT/culture logic | Use this as a branch point for review, tables, and practice questions. |
| Safety and referral | some agents require special handling | Use this as a branch point for review, tables, and practice questions. |
Spirochete Study Map
| Organism/group | Main transmission or exposure | Disease anchors | Best study testing logic |
|---|---|---|---|
| Treponema pallidum subsp. pallidum | Sexual contact and congenital transmission | Syphilis: primary chancre, secondary rash/systemic disease, latent infection, tertiary disease, neurosyphilis, congenital disease | Use nontreponemal and treponemal serology together; direct detection is specialized and culture is not routine |
| T. pallidum subsp. pertenue | Skin-to-skin spread through infectious lesions in warm humid regions | Yaws with skin lesions and possible late destructive bone/soft tissue disease | Serology resembles syphilis; geography and syndrome separate the diagnosis |
| T. pallidum subsp. endemicum | Close personal contact and shared utensils in endemic settings | Endemic nonvenereal syphilis with mucocutaneous disease and possible late destructive lesions | Testing does not reliably distinguish subspecies without clinical and epidemiologic context |
| Treponema carateum | Skin contact with infectious lesions in focal endemic areas | Pinta with skin lesions and pigmentary changes rather than classic venereal syphilis | Serology can overlap with other treponemal infections; exposure history matters |
| Borrelia burgdorferi complex | Ixodes tick exposure in endemic regions | Lyme disease with erythema migrans, neurologic, cardiac, or joint manifestations depending on stage | Two-step serology is common after early localized disease; early testing can be negative |
| Relapsing fever Borrelia | Soft ticks or body lice depending on species and region | Recurrent fever episodes with spirochetes sometimes visible during febrile periods | Direct blood smear or molecular/reference testing may matter during fever; exposure pattern is central |
| Leptospira interrogans group | Urine-contaminated water, soil, animals, flooding, or occupational exposure | Leptospirosis ranging from febrile illness to jaundice, renal disease, pulmonary hemorrhage, or meningitis | Specimen timing changes yield: blood/CSF early, urine later; serology/reference methods are common anchors |
Treponemal Disease Pattern Table
| Disease pattern | Usual patient/exposure clue | Clinical memory anchors | Testing warning |
|---|---|---|---|
| Venereal syphilis | Sexual exposure or congenital risk | Primary painless lesion, secondary rash including palms/soles, latent stage, late neurologic/cardiovascular/gummatous possibilities | No single serologic result tells the whole story; stage, history, treatment, and titer trend matter |
| Congenital syphilis | Maternal infection during pregnancy | May involve stillbirth, neonatal disease, rash, hepatosplenomegaly, bone findings, or later dental/neurologic findings | Maternal antibody complicates interpretation; infant evaluation follows specific algorithms |
| Yaws | Child in endemic warm/humid setting with skin-to-skin exposure | Papules, ulcers, disseminated skin lesions, and possible late destructive tissue/bone disease | Routine serology cannot neatly separate yaws from syphilis without epidemiology |
| Endemic nonvenereal syphilis | Close-contact spread in arid or warm endemic regions | Oral or skin lesions with possible late destructive disease | Transmission is nonsexual; avoid assuming venereal exposure from serology alone |
| Pinta | Endemic region with skin lesion exposure | Skin papules or plaques followed by pigment changes | Mostly a skin disease pattern; serology overlaps with other treponemal infections |
Syphilis Serology Test Jobs
| Test type | Examples | What it is good for | Student caution |
|---|---|---|---|
| Nontreponemal tests | RPR and VDRL | Screening in some algorithms, estimating activity with a titer, and monitoring response after treatment | False positives and false negatives occur; results must be confirmed or interpreted with a treponemal test and clinical context |
| Treponemal tests | EIA/CIA, TP-PA, FTA-ABS, other treponemal immunoassays | Confirming exposure to T. pallidum-type antigens and supporting reverse-sequence algorithms | Often remains reactive after treated infection, so it is not a clean marker of current activity |
| CSF VDRL | VDRL performed on CSF when neurosyphilis is being evaluated | Specific supportive evidence when reactive in the right setting | A nonreactive result does not fully exclude neurosyphilis when suspicion is high |
| Quantitative titer | Reported as a dilution such as 1:2, 1:8, 1:32 | Follow disease activity and response to therapy using the same test method when possible | Compare titers carefully; small changes may not be meaningful |
| Direct detection or specialized testing | Darkfield, DFA, PCR/reference workflows depending on lesion and setting | Can support diagnosis from appropriate lesions or specimens | Not routine for every lab and can be limited by specimen quality and availability |
RPR and VDRL Reading Pitfalls
| Concept | RPR/VDRL study meaning | Why students care |
|---|---|---|
| Reagin-based reaction | These tests detect antibodies reacting with cardiolipin-type antigen material, not a unique whole-organism marker | Explains biologic false positives and why confirmation is needed |
| Flocculation endpoint | Reactive samples show visible clumping or particle aggregation by the method used | Reading time, rotation/mixing, and drying can change appearance |
| Specimen limits | Hemolysis, lipemia, contamination, heat handling, or wrong specimen type can interfere depending on method | Preanalytic problems can create confusing results |
| Prozone effect | Very high antibody levels can rarely make an undiluted test look falsely nonreactive | Dilution may be needed when clinical suspicion and result disagree |
| False-positive settings | Pregnancy, autoimmune disease, some viral infections, injection drug use, older age, and other infections can be associated | A reactive screen is not automatically syphilis |
| False-negative timing | Very early infection and some late or treated patterns can be nonreactive | A negative result does not always end the workup if the syndrome fits |
Traditional and Reverse Syphilis Algorithms
| Algorithm | First test | If first test is reactive | Main interpretation habit |
|---|---|---|---|
| Traditional sequence | Start with RPR or VDRL | Confirm with a treponemal test such as TP-PA or another specific assay | Good for finding active reagin response, but early or treated patterns can be missed |
| Reverse sequence | Start with treponemal EIA/CIA or similar assay | Perform quantitative RPR/VDRL; if discordant, use a second treponemal test | Can detect past treated infection or early infection, but discordant results need careful sorting |
| Both tests reactive | Treponemal and nontreponemal tests agree | Stage, symptoms, treatment history, and titer guide next interpretation | Do not stop at "positive"; ask active, past, treated, reinfection, or congenital risk |
| Treponemal reactive but RPR/VDRL nonreactive | Common reverse-algorithm discordance | Second treponemal test and history help separate past infection, early infection, false positive, or treated disease | This pattern is not automatically active syphilis |
| RPR/VDRL reactive but treponemal test nonreactive | Possible biologic false positive or technical/context issue | Review risk, symptoms, specimen, and repeat/confirm strategy by policy | Avoid diagnosing syphilis from a lone reagin result |
Syphilis Stage and Test Sensitivity Anchors
| Stage | Nontreponemal test tendency | Treponemal test tendency | Practical warning |
|---|---|---|---|
| Very early primary | May still be nonreactive | May also be negative early | Lesion timing can precede serologic positivity |
| Primary | Often reactive but less sensitive than in secondary disease | Usually becomes reactive as immune response develops | A compatible lesion may need repeat testing or direct/specialized evaluation |
| Secondary | Usually strongly reactive | Usually reactive | High antibody levels can rarely cause prozone with nontreponemal testing |
| Latent | May remain reactive, sometimes at lower titers | Usually reactive | History and prior treatment decide meaning |
| Late disease or treated infection | Can decline or become nonreactive after treatment or over time | Often remains reactive for life | Treponemal positivity alone does not prove active disease |
Exact sensitivity varies by assay and patient setting. Use this table as a study anchor, not as a substitute for current laboratory policy.
Lyme Serology Two-Step Logic
| Step | Result pattern | Interpretation habit | Student trap |
|---|---|---|---|
| Initial immunoassay | Negative | Usually no further serology if pretest probability is low or compatible illness is not present | Early localized disease can test negative, especially with short symptom duration |
| Initial immunoassay | Positive or equivocal | Reflex to a second-tier test by the lab algorithm | Do not report the screen alone as final proof |
| Second-tier immunoblot or second immunoassay | Positive by criteria | Supports exposure/infection in the right clinical setting | Serology does not distinguish every active versus past infection question |
| Second-tier test | Negative after reactive screen | Usually interpreted as not supported serologically, with repeat testing only if timing and clinical suspicion justify it | A single early negative algorithm can miss evolving antibody response |
| Neuroborreliosis concern | Serum plus CSF evaluation may be considered by specialized criteria | Paired context helps avoid overcalling nonspecific CSF findings | Routine serum logic alone may not answer neurologic questions |
C. trachomatis Syndrome Map
| Serovar lane | Syndrome anchors | Transmission or source clue |
|---|---|---|
| A-C | Trachoma with chronic ocular infection and scarring risk | Eye-to-eye spread, contaminated hands, fomites, and flies in endemic settings |
| D-K | Urethritis, cervicitis, PID, epididymitis, proctitis, neonatal conjunctivitis, or neonatal pneumonia | Sexual transmission, autoinoculation, infected secretions, or perinatal exposure |
| L1-L3 | Lymphogranuloma venereum with invasive lymphatic disease | Sexual transmission; presentation may include proctocolitis or lymphadenopathy depending on exposure site |
Chlamydia Testing and Specimen Logic
| Patient or specimen context | Most useful testing anchor | Student warning |
|---|---|---|
| Urogenital screening in women | Vaginal swab or first-catch urine NAAT depending on collection strategy and test validation | Do not assume every specimen type is validated for every platform |
| Urogenital screening in men | First-catch urine or urethral specimen NAAT depending on setting | Collection timing and specimen type matter |
| Rectal or pharyngeal exposure | Site-specific NAAT when validated and clinically indicated | A genital-only test can miss exposed sites |
| Neonatal conjunctivitis or pneumonia concern | Conjunctival or respiratory-site testing by validated methods | Neonatal disease is not the same workflow as adult screening |
| Trachoma or LGV suspicion | Clinical syndrome plus specialized testing or public health workflow when needed | Serovar and syndrome context change interpretation |
Rickettsial Testing Pitfalls
| Concept | Why it matters | Student takeaway |
|---|---|---|
| Serology timing | Antibodies may not be detectable early in illness | A negative early result does not always exclude disease |
| PCR specimen choice | PCR yield depends on organism, timing, and specimen type | Use appropriate material and clinical context |
| Weil-Felix reaction | Historical cross-reaction test with poor sensitivity and specificity | Know it as legacy exam history, not a preferred modern diagnostic path |
| Blood smear morulae | Can support Ehrlichia or Anaplasma suspicion when seen | Absence does not rule out infection |
| Geography and vector history | Agent probability changes by ticks, lice, fleas, mites, travel, and region | Exposure history is part of the lab workup |
Mycoplasma and Ureaplasma Study Anchors
| Organism/group | Where students should place it | Clinical anchors | Testing or culture warning |
|---|---|---|---|
| Mycoplasma pneumoniae | Respiratory tract pathogen without a cell wall | Atypical pneumonia, tracheobronchitis, school-age or young adult respiratory illness, and occasional extrapulmonary associations | NAAT or serology may be used; culture is slow and specialized |
| Mycoplasma genitalium | Urogenital pathogen | Nongonococcal urethritis and cervicitis or PID-associated concern | NAAT is the practical anchor; resistance-guided therapy may matter clinically |
| Mycoplasma hominis | Genital tract colonizer or opportunist | Postpartum or postprocedural infection, PID-associated context, neonatal or immunocompromised-host infection in selected cases | Often colonization; source and syndrome decide significance |
| Ureaplasma urealyticum/parvum | Genital tract colonizers or opportunists; urease-positive lane | Urogenital disease associations, pregnancy or neonatal contexts, and invasive disease in selected hosts | Interpret cautiously because colonization is common |
| Other oral/genital Mycoplasma-like flora | Oropharynx or genital tract depending on species | Usually colonization or unclear significance | Do not make disease from a name alone |
Mycoplasma Collection and Culture Concepts
| Concept | Study meaning | Pitfall |
|---|---|---|
| No classic cell wall | Beta-lactam logic does not fit Mycoplasma or Ureaplasma | Do not apply routine cell-wall drug assumptions |
| Fastidious growth | Special media, serum or sterol support, and prolonged incubation may be needed | Routine bacterial plates are not the workflow |
| Transport quickly when culture is attempted | Fragile organisms and low burden can reduce recovery | Delayed or dried specimens weaken results |
| Body fluid or liquid specimens | May require concentration and special handling before inoculation | Routine processing can miss the target |
| Swabs | Need suitable transport medium and validated testing | A standard dry swab may be unacceptable depending on method |
| Urease, arginine, and glucose reactions | Classic differentiation anchors for Ureaplasma and selected Mycoplasma groups | Modern labs often use molecular methods rather than classic culture differentiation |
Basic workflow
- Define the main question for spirochetes, cell-wall-deficient, and intracellular agents.
- Separate screening clues from confirmatory information.
- Connect the topic to specimen quality, method limits, and clinical context.
- Use tables to compare similar organisms, methods, or syndromes.
- Circle back to tools or deep guides only after the core concept is clear.
How to read it
- Treponemes: venereal and nonvenereal disease patterns, serology algorithms, and titer follow-up
- Borrelia and Leptospira: exposure history, staged illness, and specimen timing organize testing
- Chlamydia/Rickettsial agents: intracellular biology changes culture and testing expectations
- Mycoplasma/Ureaplasma: no cell wall, special collection, and NAAT/culture logic
- Safety and referral: some agents require special handling
High-yield trapCommon mistakes
- Memorizing names without knowing the organizing branch.
- Forgetting specimen source and patient context.
- Treating a screening clue as a final answer.
ShortcutStudent shortcut
For spirochetes, cell-wall-deficient, and intracellular agents, learn the organizer first, then add exceptions.